About 678 results

ALLMedicine™ Prolactinoma Center

Research & Reviews  263 results

Management of prolactinomas in children and adolescents; which factors define the respo...
https://doi.org/10.1007/s11102-021-01184-x 10.1007/s11102-005-5079-0 10.1111/j.1365-2265.2009.03667.x 10.1210/jc.2006-1668 10.1530/eje-14-0144 10.1530/eje-15-0189 10.1007/s11102-021-01146-3 10.1007/s00431-017-3042-5 10.1007/s11102-020-01120-5 10.1046/j.1365-2265.2003.01748.x 10.1007/s11102-008-0149-8 10.1210/jcem.83.8.5001 10.1210/jcem.79.4.7525627 10.1016/j.wneu.2015.11.046 10.1093/neuros/nyy204 10.1159/000497331 10.1136/bmj.2.5816.743 10.1056/nejm199410063311403 10.1210/jc.2018-01071 10.1530/eje-13-0231 10.1056/NEJMoa054830 10.1007/s40263-015-0293-4 10.1016/j.ando.2020.12.008 10.1210/jc.2010-1692 10.1136/adc.51.3.170 10.1016/s0022-3476(97)90000-7 10.3171/2010.11.Jns101369 10.1111/cen.13156 10.3389/fendo.2020.00527 10.1111/cen.14394 10.1210/jc.2014-3670 10.1507/endocrj.EJ17-0268 10.1515/jpem-2018-0475 10.4274/jcrpe.galenos.2018.2018.0206 10.1016/j.eprac.2020.09.001 10.1186/s13098-015-0094-4 10.4103/2230-8210.176346 10.1007/978-3-319-12114-7_1 10.1111/jne.12702 10.1523/jneurosci.4415-12.2013 10.1530/joe-15-0213 10.4158/ep-2018-0034 10.1530/eje-12-0763 10.1089/gtmb.2018.0133 10.1111/j.1399-0004.2010.01406.x 10.3390/jcm9062003 10.1016/j.nec.2019.05.001 10.1159/000486280 10.1210/jcem.84.7.5810 10.1210/jcem.86.11.8054 10.1530/eje-09-0012 10.1007/bf03346388 10.1210/er.2005-9998 10.1097/md.0000000000014380 10.1227/00006123-199402000-00001 10.1016/s0090-3019(02)00714-0 10.3171/jns.1994.80.2.0209 10.1515/jpem.2000.13.3.261 10.1210/jc.2007-2758 10.1111/j.1365-2362.2010.02399.x 10.1111/cen.12149 10.1210/clinem/dgz144 10.1007/s12020-018-1638-9 10.1007/s11102-008-0162-y 10.1007/s11102-013-0473-5 10.1016/0002-9378(81)90553-6 10.1210/jcem-68-2-412
Pituitary Alikasifoglu A, Celik NB et. al.

Sep 15th, 2021 - Prevalence, presentation and clinical outcome of prolactinomas vary in children and adults. In this study, we evaluated the clinical features and outcome of children and adolescents with prolactinoma to identify the differences from that of adults...

Shrinkage by the third month predicts long-term response of macroprolactinoma after cab...
European Journal of Endocrinology; Biagetti B, Sarria-Estrada S et. al.

Aug 11th, 2021 - Transsphenoidal surgery (TSS) is mainly indicated in prolactinomas when dopamine agonist treatment fails. However, there is no established early predictor of cabergoline (CBG) response. The present study was aimed to identify predictors of CBG res...

Severe obesity caused by prolactinoma related to the abnormal insulin metabolism-A case...
Obesity Research & Clinical Practice; Yan JP, Han ZP et. al.

Aug 3rd, 2021 - The relationship between prolactinoma and obesity has not been well explained yet. This report introduced the diagnosis and treatment course of a severely obese male patient. After a series of examinations, the patient was finally diagnosed as pro...

Determinants of Surgical Remission in Prolactinomas: A Systematic Review and Meta-Analy...
World Neurosurgery; Wright K, Chaker L et. al.

Jul 30th, 2021 - Prolactin-secreting tumors respond well to medical management, with a few patients requiring surgery. We conducted a systematic review and meta-analysis to study the determinants of surgical remission in these tumors. We searched PubMed to identif...

Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas.
https://doi.org/10.1007/s11102-021-01168-x 10.1001/jama.2016.19699 10.1007/s11102-012-0454-0 10.1210/jc.2010-0537 10.1016/j.beem.2019.101290 10.3803/EnM.2020.35.2.237 10.1210/jc.2010-1692 10.1210/jcem-60-4-698 10.1210/er.2005-9998 10.1517/14656566.1.3.555 10.1210/jcem.84.7.5810 10.1056/NEJMoa054830 10.4065/74.4.371 10.1186/s12902-020-0507-8 10.1210/clinem/dgz076 10.1210/jc.2018-02202 10.1210/jc.2008-2103 10.1007/s11102-010-0283-y 10.3171/2011.1.FOCUS10317 10.1530/EJE-07-0248 10.3803/EnM.2014.29.3.280 10.1016/j.wneu.2016.08.088 10.3171/jns.2002.97.2.0307 10.1007/s11102-019-01001-6 10.1111/j.1365-2265.2006.02493.x 10.1136/bmj.2.5816.743 10.1056/NEJM199410063311403 10.1210/jc.2009-1238 10.1210/clinem/dgaa744 10.1111/cen.13339 10.1007/s40618-020-01478-0 10.3389/fendo.2015.00085 10.1007/s11102-010-0261-4 10.1136/bcr-2017-220971 10.1530/EJE-16-0087 10.3389/fendo.2018.00636 10.1210/clinem/dgz144 10.1007/s40618-021-01569-6 10.3346/jkms.2021.36.e97 10.1210/jcem.87.7.8645 10.1055/a-1247-4908 10.1159/000180098 10.1007/s11102-019-01016-z 10.3389/fendo.2020.00439 10.1016/j.clineuro.2013.02.016 10.1007/s11102-018-0904-4 10.1007/s12020-016-1115-2
Pituitary Park JY, Choi W et. al.

Jul 1st, 2021 - Dopamine agonists (DAs) have long been the recommended first-line treatment for prolactinoma. Given the remarkable developments in surgical techniques, however, surgery is on the rise. We compared the treatment outcomes of patients with noninvasiv...

see more →

Guidelines  1 results

Pituitary incidentaloma: an endocrine society clinical practice guideline.
The Journal of Clinical Endocrinology and Metabolism; Freda PU, Beckers AM et. al.

Apr 9th, 2011 - The aim was to formulate practice guidelines for endocrine evaluation and treatment of pituitary incidentalomas. Consensus was guided by systematic reviews of evidence and discussions through a series of conference calls and e-mails and one in-per...

see more →

News  7 results

Prolactin, the pituitary, and pregnancy: Where’s the balance?
Clinical Endocrinology News;

Apr 26th, 2018 - What if the tumor grows in pregnancy? During pregnancy, high estrogen levels from the placenta can stimulate prolactinoma growth, and the dopamine agonist’s inhibitory effect is gone once that medication’s been stopped. This means that “We have bo.

Pituitary Incidentaloma

Jan 26th, 2015 - SHOULD AN ASYMPTOMATIC PATIENT BE EVALUATED FURTHER? Endocrine Society guidelines2 recommend that all patients with pituitary incidentaloma, with or without symptoms, should undergo a complete history and physical examination and laboratory evalua.

Prolactinoma: A Case Study

Nov 1st, 2011 - Dopamine agonists are approximately 80% to 90% effective in decreasing prolactin levels and reducing tumor size in microadenomas and 60% to 70% in macroadenomas. The major drawback of using medication is that it does not always provide permanent r.

Endocrine Society Releases Guidelines on Pituitary Incidentalomas
Elizabeth Mechcatie

Apr 20th, 2011 - Surgical treatment of a pituitary incidentaloma is recommended when the lesion is causing a visual field deficit or other visual abnormalities, such as ophthalmoplegia "or neurological compromise," according to evidence-based clinical practice gui.

The Case of the Famous Woman With a Bloated Belly

Jan 11th, 2010 - How Would Mary Have Been Treated Today? Today, when a woman suspects pregnancy, she undergoes a rapid test for pregnancy. If the result is negative but symptoms, such as galactorrhea or amenorrhea, are still present, an occult prolactinoma might b...

see more →